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Introduction: Expression of indoleamine 2,3-dioxygenase (IDO) in primary breast cancer increases tumor growth
and metastasis. However, the clinical significance of stromal IDO and the regulation of stromal IDO are unclear.
Methods: Metabolomics and enzyme-linked immunosorbent assay (ELISA) were used to study the effect of
cyclooxygenase-2 (COX-2)-overexpressing breast cancer cells on IDO expression in co-cultured human breast
fibroblasts. Biochemical inhibitors and short-hairpin RNA (shRNA) were used to clarify how prostaglandin E2
(PGE2) upregulates IDO expression. Associations of stromal IDO with clinicopathologic parameters were tested in
tumor specimens. An orthotopic animal model was used to examine the effect of COX-2 and IDO inhibitors on
tumor growth.
Results: Kynurenine, the metabolite generated by IDO, increases in the supernatant of fibroblasts co-cultured with
COX-2-overexpressing breast cancer cells. PGE2 released by cancer cells upregulates IDO expression in fibroblasts
through an EP4/signal transducer and activator of transcription 3 (STAT3)-dependent pathway. Conversely,
fibroblast-secreted kynurenine promotes the formation of the E-cadherin/Aryl hydrocarbon receptor (AhR)/S-phase
kinase-associated protein 2 (Skp2) complex, resulting in degradation of E-cadherin to increase breast cancer
invasiveness. The enhancement of motility of breast cancer cells induced by co-culture with fibroblasts is
suppressed by the IDO inhibitor 1-methyl-tryptophan. Pathological analysis demonstrates that upregulation of
stromal IDO is a poor prognosis factor and is associated with of COX-2 overexpression. Co-expression of cancer
COX-2 and stromal IDO predicts a worse disease-free and metastasis-free survival. Finally, COX-2 and IDO inhibitors
inhibit tumor growth in vivo.
Conclusion: Integration of metabolomics and molecular and pathological approaches reveals the interplay
between cancer and stroma via COX-2, and IDO promotes tumor progression and predicts poor patient survival.Background
Chronic inflammation is strongly associated with the de-
velopment of cancer [1-3]. One of the crucial mediators of
inflammatory reaction is cyclooxygenase (COX). The
COX family of enzymes comprises two members (COX-1
and COX-2) and is the main controller of eicosanoid
biosynthesis. Studies of human breast tumor tissues dem-
onstrate that upregulation of COX-2 has been detected in* Correspondence: hung1228@nhri.org.tw
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this article, unless otherwise stated.approximately 40% of human breast tumor tissues, as well
as preinvasive ductal carcinoma in situ lesions [4]. Ele-
vated expression of COX-2 is associated with large tumor
size, advanced histologic grade, axillary node metastasis,
and unfavorable disease-free survival [4,5]. In addition,
COX-2 expression also links with increased tumor
angiogenesis [6]. Epidemiologic investigations suggest that
use of nonsteroidal antiinflammatory drugs or selective
COX-2 inhibitors reduces breast cancer risk [7,8].
Results of animal study also support an oncogenic role
of COX-2. Transgenic COX-2 overexpression induces
mammary tumor formation in mice [9]. This tumori-
genic transformation is highly dependent on PGE2 pro-
duction and angiogenic switch. In addition, HER-2/Neuicensee BioMed Central Ltd. This is an Open Access article distributed under the
icense (http://creativecommons.org/licenses/by/4.0), which permits unrestricted
ium, provided the original work is properly credited. The Creative Commons
ivecommons.org/publicdomain/zero/1.0/) applies to the data made available in
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genesis are dramatically attenuated in COX-2 knockout
mice, suggesting a key role of COX-2 in breast cancer
[10]. Recent studies also show that COX-2 inhibitors
exhibit antitumor and antiangiogenic activities in vivo
and exhibit chemopreventive effects against mammary
carcinogenesis induced by 7,12-dimethyl-benz(a)anthracene
in rats [11]. All of the results suggest that COX-2 is in-
volved in multiple steps of breast carcinogenesis and is
a potential target for cancer prevention and therapy.
Interplay between breast cancer cells and cancer-
associated fibroblasts (CAFs), the most abundant and
active stromal cells, is crucial for tumor growth, pro-
gression, angiogenesis, and therapeutic resistance [12].
Cancer cells release a number of factors to enhance the
production of cytokines, chemokines, and matrix metallo-
proteinases (MMPs) from CAFs, which in turn facilitate
cancer cell proliferation, migration, and invasion. Previous
study demonstrated that stromal fibroblasts present in
invasive breast carcinomas can secrete large amounts of
stromal cell-derived factor 1 (SDF-1) to enhance tumor
growth and angiogenesis [13]. Co-injection of breast can-
cer cells and fibroblasts also promotes the progression of
ductal carcinoma in situ to invasive breast carcinoma by
stimulating chemokine (C-X-C motif) ligand 14 (CXCL14)
and chemokine (C-X-C motif ) ligand 12 (CXCL12)
production [14]. However, most studies addressing the
crosstalk between cancer and stromal cells focus on
protein factors like cytokines and chemokines. Whether
other small molecules such as lipids or metabolites
participate in cancer-stromal cell interaction is largely
unknown.
The tumor-promoting role of CAFs via upregulation of
COX-2 in ductal carcinoma in situ of the breast was first
demonstrated by Hu et al. [15]. The authors showed that
co-culture with fibroblasts increases COX-2 expression in
breast cancer cells and subsequently induces MMP-9 and
MMP-14 in these cells to promote invasion. They also
elucidated the underlying mechanism by demonstrating
that inhibition of nuclear factor kappa-light-chain-enhancer
of activated B cells (NF-κB) and COX-2 activity reduces the
invasion-promoting effect of fibroblasts. These data suggest
that fibroblasts secrete some factors to activate NF-κB-
mediated transcription of COX-2 in breast cancer cells
to enhance tumor progression.
However, several issues remain elusive. First, does PGE2
generated by COX-2-expressing cancer cells also affect gene
expression or behavior of stromal fibroblasts? Second,
do CAFs secrete small molecules (other than proteins
or peptides) to regulate cancer cell invasion? Finally,
can the importance of cancer-stroma interaction in cancer
progression be validated in clinical samples?
In this study, we address these questions and try to
clarify the underlying mechanism.Methods
Cell culture
Human breast cancer cell lines MCF-7 and MDA-MB-231
were purchased from the Bioresource Collection and
Research Center (BCRC) and ATCC. Immortalized human
breast fibroblasts, RMF-EG [16], were kindly provided by
Dr. Charlotte Kuperwasser (Tufts University, Boston, MA,
USA). These cells were cultured in DMEM/F12 containing
10% fetal bovine serum (FBS). Other experimental materials
and procedures are provided in Additional file 1.
Establishment of inducible COX-2-expression MCF-7 cell line
To establish an inducible COX-2-expression cell line,
MCF-7 cells (1 × 106) were resuspended in buffer R
containing 2 μg pCMV-Tet3G plasmid. Transfection
was performed by using Neon microporation transfection
system at room temperature with 1,250 V, 20 milliseconds,
and two pulses. After 48 hours, the cells were selected
with 1 mg/ml G418 for 2 weeks.
For the delivery of the second plasmid, pCMV-Tet3G sta-
bly transfected cells (1 × 106) were resuspended in buffer R
containing 2 μg of pTRE-mCherry-COX-2 plasmid. Trans-
fection was performed by using Neon microporation trans-
fection system at room temperature with 1,250 V, 20
milliseconds, and two pulses. After 48 hours, the cells were
subjected to selection with 100 μg/ml hygromycin B. The
stable cell line harbors both pCMV-Tet3G and pTRE-
mCherry-COX-2 plasmid was used for induction experi-
ment. The cells were maintained at 37°C in a 5% CO2-hu-
midified atmosphere and were incubated with doxycycline
to induce COX-2 expression before co-culture assay.
Co-culture assay
In the co-culture system, 1 × 105 RMF-EG cells were grown
in the bottom of a six-well plate in DMEM/F12 with
10% FBS, and 1 × 106 breast cancer cells were seeded on
the 0.4-μm polyester membrane of a transwell insert in
the same medium. MCF-7 cells were treated with or with-
out doxycycline (1 μg/ml) for 72 hours. The conditioned
medium, breast cancer cells, and RMF-EG cells were har-
vested for metabolomics and Western blotting analysis.
Metabolite profiling
The proteins in the conditioned medium were removed
by using 3-kDa ultracentrifugation filter devices. The
metabolites in the filtered medium were extracted by
using iced 50% methanol and were subsequently dried
by a speedvac. Metabolite profiles were analyzed with
the Metabolomics Core of National Health Research
Institutes by using a high-resolution ultraperformance
liquid chromatography (UPLC) coupled online to a
triple-quadrupole time-of-flight mass spectrometry system,
as described previously [17]. Metabolite identity was
predicted with Human Metabolome Database [18].
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transcription-PCR analysis
Total RNA was isolated from cells by using an RNA ex-
traction kit (Qiagen, Valencia, CA, USA) and 1 μg of
RNA was reverse-transcribed to cDNA. Target mRNAs
were quantified by using real-time PCR reactions with
SYBR green fluorescein, and actin served as an internal
control. cDNA synthesis was performed at 95°C for 3 mi-
nutes, and the conditions for PCR were 28 cycles of de-
naturation (95°C/1 minute), annealing (60°C/1 minute)
extension (72°C/1 minute), and 1 cycle of final extension









CAAA-3′.Immunoprecipitation and Western blot analysis
MCF-7or COX-2-overexpressing MCF-7 cells were treated
with or without 100 μM kynurenine for 24 hours; the cells
were harvested with an RIPA buffer (50 mM Tris–HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 0.1% SDS, 0.5% sodium
deoxycholate, 2 mM EDTA, and 50 mM NaF), and cellular
lysates were incubated with anti-AhR antibody overnight
at 4°C with rotation. Immunocomplexes were pulled down
by Protein-G agarose bead, washed with RIPA buffer 3
times, and eluted with a sample buffer in boiled water
for 10 minutes. The eluted samples were subjected to
SDS-PAGE separation, and proteins were transferred to
nitrocellulose membranes. Finally, the blots were probed
with anti-E-cadherin or anti-Skp2 antibody and developed
with enhanced chemiluminescence reagent.Migration assay
Migration assays were conducted in transwells with
8-μm-pore filter inserts. Then 1 × 104 MCF-7 or
COX-2-overexpressing MCF-7 cells were seeded in
the upper chamber. The lower chambers were filled
with DMEM medium containing 1% FBS and 100 μM
kynurenine. After 24 hours, the cells on the upper
surface were removed by wiping with a cotton swab,
and the cells that migrated to the lower surface were
fixed. The cells were stained with 4′,6-diamidino-2-
phenylindole (DAPI), and the cell number in 15 ran-
domly selected fields was counted under a microscope
(100×). Experiments were performed independently at
least 3 times.Protein ubiquitination assay
MCF-7 cells treated with or without kynurenine were incu-
bated with the proteasome inhibitor MG132 or the lyso-
some inhibitor chloroquine. The cells were harvested with
a lysis buffer (20 mM Tris–HCl at pH 7.5, 150 mM sodium
chloride, 1 mM calcium chloride, and 1% Triton X-100
and protease inhibitors), and cellular lysates were incu-
bated with an E-cadherin antibody overnight at 4°C with
rotation. Protein-G beads were added to the samples and
incubated for another 1 hour at 4°C. Immunocomplexes
were eluted and were subjected to SDS-PAGE separation,
and proteins were transferred to nitrocellulose membranes.
Finally, the blots were probed by using an anti-ubiquitin
antibody to detect the ubiquitination status of E-cadherin.
Immunofluorescent staining and confocal microscopy
MCF-7 cells were treated with or without 100 μM kynure-
nine for 6 hours and fixed with 3.7% formaldehyde for
15 minutes at room temperature. Cells were washed twice
with PBS and permeabilized by 0.1% Triton X-100 solution
for 10 minutes. After permeabilization, cells were
incubated with 0.05% BSA solution to block nonspecific
binding. Anti-AhR mouse monoclonal antibody (1:80) or
anti-E-cadherin goat polyclonal antibody (1:250) was added
and incubated at room temperature for 1 hour. After ex-
tensive washing, Alexas Fluro 594 anti-mouse IgG or
Alexas Fluro 488 anti-goat IgG was added and incubated
for another 1 hour. Cell nuclei were stained with DAPI so-
lution. Finally, coverslips were washed twice with PBS and
subsequently placed in mounting solution. The fluorescent
image was observed under a confocal microscope.
In vivo orthotopic animal study
MCF-7 or MCF-7-COX2 (8 × 106) cells were mixed with
RMF-EG (6 × 106) cells in Hanks balanced salt solution
and Matrigel (BD Transduction Laboratories, San Jose,
CA, USA). Cells were inoculated into the fourth
mammary fat pads of 6-week-old female BALB/cAnN.Cg-
Foxn1nu/CrlNarl mice. Before the inoculation of the
cancer cell/fibroblast mixture, all mice were primed with
6 mg/kg of 17β-estradiol twice a week for 3 weeks.
After inoculation, 17β-estradiol was continuously given
to mice throughout the experiments. Measurement of
tumor growth was begun at 4 weeks after injection, and
tumor volume was calculated by using the equation: tumor
volume = (length × width2)/2. After 10 weeks, mice injected
with COX-2-overexpressing MCF-7 and RMF-EG pro-
duced tumors with volumes approximately 200 mm3 and
were randomly divided into four groups that received ve-
hicle (DMSO), NS-398 (10 mg/kg), L-1-methy-tryptophan
(10 mg/kg), or both inhibitors 5 times per week.
Two weeks later, animals were killed, and tumors were
isolated from mice. The statistical difference between ex-
perimental groups was evaluated with repeated-measures
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approved by the Institutional Animal Care and Use
Committee of National Health Research Institutes.
Patients and statistical analysis
Paraffin-embedded human breast tumor tissues were
obtained from Chi-Mei Medical Center (Tainan, Taiwan)
between 1998 and 2004. The slides were stained with
anti-COX-2 or anti-IDO antibodies. The COX-2 and
IDO stainings were interpreted by using the H-score,
defined by the following equation: H-score = ΣPi (i + 1),
as previously described [19], where i is the intensity of
the stained tumor cells (0 to 3+), and Pi is the percentage
of stained tumor cells with various intensities. We classi-
fied tumors with cancer cells and stromal cells showing
H-scores no less than the median of all scored cases as
having high COX-2 and IDO expression, respectively.
The follow-up duration ranged from 5.4 to 143.6 months,
with a mean of 87.1 months. Survival analyses for disease-
specific and metastasis-free survival were performed by
using Kaplan-Meier plots and compared by using the
log-rank test. The correlation between COX-2 and IDO
expression with clinicopathologic parameters was examined
with χ2 test. P value < 0.05 was considered statistically
significant. This study was approved by the Research
Ethics Committee of National Health Research Institutes.
Written informed consent was obtained from all patients
participating in this study.
Results
COX-2-overexpressing breast cancer cells upregulated
IDO expression in co-cultured fibroblasts
We analyzed the metabolite profile of the supernatant of
RMF-EG human breast fibroblasts co-cultured with
MCF-76 or COX-2-overexpressing MCF-7 cells and
found that several metabolites were increased in the
supernatant of COX-2-overexpressing MCF-7/RMF-EG
co-culture. A peak with the m/z ratio of 209 was increased
about twofold (Figure 1A). By using Human Metabolome
Database search, a candidate metabolite was predicted to
be kynurenine. UPLC/MS/MS analysis demonstrated that
fragmentation of kynurenine standard yielded three peaks
with m/z ratio of 209, 192, and 146, which is consistent with
the reported data (accession: K0009019, MassBank, [20])
(Figure 1B). Significant increase of kynurenine was con-
firmed with an ELISA assay (Figure 1C).
The rate-limiting enzymes in the generation of kynurenine
are indoleamine 2,3-dioxygenase (IDO) and tryptophan
2,3-dioxygenase (TDO). We found a 2.5-fold of increase
of IDO mRNA in RMF-EG cells co-cultured with COX-
2-overexpressing MCF-7 cells, whereas the expression
of TDO was not changed (Figure 1Di). A similar increase
of IDO protein level was also found (Figure 1Dii). IDO
was very low or undetectable in MCF-7- and COX-2-overexpressing MCF-7 cells, indicating that the kynur-
enine in the co-cultured medium was produced mainly
by RMF-EG cells (Figure 1E). Co-culture of the COX-
2-overexpressing MDA-MB-231 cells also upregulated
IDO expression in RMF-EG cells (Figure 1F). These
data suggest that COX-2-overexpressing breast cancer
cells stimulate IDO expression and increase kynure-
nine secretion in co-cultured fibroblasts.
PGE2 transcriptionally elevated IDO expression in RMF-EG
fibroblasts through the EP4/STAT3 signaling pathway
We found that PGE2 increased IDO mRNA and protein
levels in RMF-EG cells (Figure 2Ai and 2Aii). In addition,
our data showed that only PGE2-alcohol (an EP4 agonist)
significantly upregulated IDO expression (Figure 2B).
Knockdown of EP4 abolished PGE2-induced increase of
IDO in these cells (Figure 2Ci and 2Cii). By using different
IDO deletion promoters, we demonstrated that PGE2 stim-
ulated IDO transcription via the −1,140/-844 region from
the transcription start site (see Additional file 2: Figure S1).
This region contained two potential γ-interferon-activated
sites (GASs) that could be activated by different signal
transducer and activator of transcription (STAT) proteins
[21,22]. Both STAT1 and STAT3 have been implicated in
the regulation of IDO expression [23,24].
We performed a ChIP assay and found that the binding of
STAT3 to IDO promoter was increased in RMF-EG cells
co-cultured with COX-2-overexpressing MCF-7 cells,
whereas the binding of STAT1 was decreased (see
Additional file 3: Figure S2). Knockdown of STAT3 abolished
the increase of IDO induced by the EP4 agonist in RMF-EG
cells (Figure 2D). Ectopic expression of STAT3 upregulated
IDO (2.8-fold) in these cells (Figure 2E). Thus, COX-2-
overexpressing breast cancer cells upregulate IDO expres-
sion in fibroblasts through the PGE2/EP4/STAT3 pathway.
IDO-expressing fibroblasts enhanced the migration of
breast cancer cells through downregulation of E-cadherin
We next studied the effect of kynurenine on breast can-
cer cells. Kynurenine did not affect the proliferation of
MCF-7 cells (Figure 3A). However, kynurenine signifi-
cantly increased the motility of MCF-7 and COX-2-
overexpressing MCF-7 cells (Figure 3B). The conditioned
medium of RMF-EG fibroblasts preincubated with COX-2-
overexpressing MCF-7 cells also increased the motility of
MCF-7 cells (Figure 3C). We used 1-methyl-L-tryptophan
to inhibit IDO activity in RMF-EG fibroblasts induced by
co-culture with COX2-overexpressing MCF-7 cells and
found that the stimulatory effect on cell motility was
blocked (Figure 3C). These data suggested that kynurenine
released by IDO-expressing fibroblasts enhanced the migra-
tion of breast cancer cells.
We investigated the expression of epithelial-to-mesenchymal
markers in kynurenine-treated breast cancer cells and found
Figure 1 Increase of IDO expression and kynurenine production in fibroblasts co-cultured with COX-2-overexpressing breast cancer
cells. (A) Metabolite profiling of the supernatant of RMF-EG fibroblasts co-cultured with MCF-7 (RMF-M) and COX-2-overexpressing MCF-7
(RMF-COX/M) cells and identified a peak with m/z ratio of 209 was increased. (B) UPLC/MS/MS fragmentation profile of the 209 (m/z) peak and
the standard (L-kynurenine). (C) Increase of kynurenine in RMF-COX/M cells determined with an ELISA assay. The results from three independent
assays were expressed as mean ± SEM. Statistical significance was evaluated with the Student t test. *P < 0.05. (D) Upregulation of IDO but not
TDO in RMF-COX/M cells was assayed with quantitative RT-PCR. The results from three independent assays were expressed as mean ± SEM.
Statistical significance was evaluated with Student t test (i). *P < 0.05. Protein level was also determined with Western blotting (ii). (E) MCF-7 cells
were treated without (C) or with doxycycline (DOX, 1 μg/ml) for 72 hours to induce COX-2 expression. Protein level of COX-2 and IDO was
studied with Western blotting. A 3.6-fold increase of COX-2 was found, whereas the expression of IDO was not detectable. (F) Protein level of
COX-2 and IDO in MCF-7 and MDA-MB-231 cells was compared. In addition, IDO expression of RMF-EG cells co-cultured with MCF-7 or
MDA-MB-231 cells was investigated.
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(Figure 3Di). E-cadherin began to decrease around 8 hours
after addition of kynurenine, and a 70% of reduction wasfound at 24 hours. However, its mRNA did not decrease
substantially (Figure 3Dii). We found that kynurenine
induced degradation of E-cadherin protein via a
Figure 2 PGE2 upregulated IDO expression in fibroblasts via the EP4/STAT3 pathway. (A) RMF-EG cells were treated with DMSO or PGE2
(2 μM) in 1% FCS medium for 48 hours. IDO mRNA (i) and protein (ii) were determined by quantitative RT-PCR and Western blotting. *P < 0.05.
(B) RMF-EG cells were treated with 17-phenyl-trinor-PGE2 (an EP1 and EP3 receptor agonist), butaprost (an EP2 agonist), or PGE2-alcohol
(an EP4 agonist) for 48 hours, and IDO expression was studied with quantitative RT-PCR. *P < 0.05. (C) RMF-EG cells were pretreated with EP4
shRNA for 24 hours and then cultured with MCF-7 (RMF-M) and COX-2-overexpressing MCF-7 (RMF-COX/M) cells for another 48 hours. (i) The IDO
mRNA level was determined with quantitative RT-PCR. (ii) Protein level of IDO and EP4 was studied with Western blotting. *P < 0.05. (D) RMF-EG
cells were pretreated with STAT3 siRNA for 24 hours and then cultured with PGE2-alcohol for another 48 hours. Protein levels of STAT3 and IDO
were determined. (E) RMF-EG cells were transfected with pcDNA or STAT3 expression vector for 48 hours. Expression of STAT3 and IDO was
studied with Western blotting.
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rescued by MG132 (proteasome inhibitor) but not
chloroquine (lysosome inhibitor) (Figure 3E). In
addition, ubiquitination of E-cadherin protein wasincreased in kynurenine-treated MCF-7 cells (Figure 3F).
These data suggest that kynurenine induces ubiquitina-
tion and degradation of E-cadherin to promote breast
cancer cell motility.
Figure 3 Kynurenine induced E-cadherin ubiquitination and degradation and increased migration of breast cancer cells. (A) MCF-7 cells
were treated with different concentrations of kynurenine for 48 hours, and cellular proliferation was investigated with MTT assay. (B) MCF-7- or
COX-2-overexpressing MCF-7 cells were treated with 100 μM kynurenine, and cell migration was studied with transwell assays. The results from
three independent assays were expressed as mean ± SEM. Statistical significance was evaluated with Student t test. *P < 0.05. (C) RMF-EG cells
were cultured in the absence or presence of IDO inhibitor 1-methyl-L-tryptophan (L-1-MT) in the lower well of the transwell unit. MCF-7- or
COX-2-overexpressing MCF-7 cells were seeded in the upper well. After 24 hours, migrated cell number was determined. *P < 0.05. (D) MCF-7 cells
were incubated without (−) or with (+) 100 μM kynurenine for different times. Protein (i) and mRNA (ii) levels of E-cadherin were studied. (E)
MCF-7 cells were incubated with kynurenine (100 μM) and MG132 (proteasome inhibitor, 10 μM) or chloroquine (CQ, lysosome inhibitor, 25 μM)
for 24 hours. Protein level of E-cadherin was studied with Western blotting and normalized to actin. (F) Ubiquitination of E-cadherin was studied
with immunoprecipitation of E-cadherin by specific antibody, and the ubiquitination status was detected with anti-ubiquitin antibody.
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AhR- and Skp2-dependent manner
Kynurenine has been shown to be an endogenous
tumor-promoting ligand of the human AhR [25]. In
addition, AhR is involved in the degradation of sexsteroid receptors via a cullin 4B-dependent ubiquiti-
nation pathway [26]. We tested whether kynurenine
reduced protein stability of E-cadherin through
activation of AhR and found that the binding
between AhR and E-cadherin was increased in
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ingly, Skp2, an F-box protein of the SCF E3 ligase,
was co-immunoprecipitated with AhR, and the inter-
action was also increased by kynurenine. We did not
detect the cullin 4B protein in the complex (data not
shown). This is not a cell line-specific effect, because
the interaction between AhR and E-cadherin protein
was also elevated in kynurenine-treated A549 cellsFigure 4 Kynurenine induced E-cadherin degradation in an AhR- and
kynurenine for 6 hours, and cellular proteins were harvested. AhR protein w
E-cadherin and Skp2 was studied with Western blotting. (B) Cells were incu
6 hours, and the co-localization of E-cadherin and AhR was studied with co
and then incubated with kynurenine for another 48 hours. The protein leve
blotting and normalized to actin level. (D) Cells were incubated with kynur
drugs for 24 hours. E-cadherin protein level was investigated with Western
assay. *P < 0.05.(see Additional file 4: Figure S3). The 3′-methylcho-
lanthrene (3-MC), another AhR ligand, also induced
co-localization of AhR and E-cadherin at the cell
membrane (Figure 4B). Knockdown of Skp2 reversed
kynurenine-induced reduction of E-cadherin protein
without affecting AhR expression (Figure 4C). The
AhR antagonist, 3′4′-dimethoxyflavone (3′4′-DMF),
also inhibited the decrease of E-cadherin induced bySkp2-dependent pathway. (A) MCF-7 cells were incubated with
as immunoprecipitated by specific antibody, and the binding of
bated with kynurenine or 3-methylcholanthrene (an AhR agonist) for
nfocal microscopy. (C) Cells were treated with Skp2 shRNA for 24 hours
ls of Skp2, E-cadherin, and AhR were determined with Western
enine, 3′4′-dimethoxyflavone (3′4′-DMF, an AhR antagonist) or both
blotting. (E) Cells were also collected and subjected to migration
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increased migration of MCF-7 cells was blocked by
3′4′-DMF (Figure 4E). These data suggest that kynur-
enine induces the formation of E-cadherin/AhR/Skp2
complex and causes E-cadherin degradation.
COX-2 expression in breast cancer and IDO expression in
stromal fibroblasts predicted poor disease-specific and
metastasis-free survival
The correlation between COX-2 expression in tumor tis-
sues and IDO expression in CAFs was confirmed by two
approaches. First, we isolated CAFs from two breast tumor
tissues without or with COX-2 overexpression and found
that IDO expression in CAFs was upregulated in COX-2-
overexpressing tumor (see Additional file 5: Figure S4).
Second, we used immunohistochemical analysis to detect
COX-2 and IDO expression in a cohort of breast cancer
tissues (Figure 5A). COX-2 expression in tumors was
positively correlated with a high IDO expression in CAFs
(65 of 101, 64%; P < 0.001) (Table 1). COX-2 was highly
expressed in stage III (19 of 24, 79%; P < 0.05), N1-N2
(61 of 85, 71%; P < 0.001), and T3-4 stage (20 of24,
83%; P < 0.05) tumor specimens. IDO expression in CAFs
was significantly expressed in stage III (20 of 24, 83%;
P < 0.05), N1-N2 (60 of 85, 71%; P < 0.001), and T3-4
stage (21 of 24, 88%; P < 0.001) tumor specimens. The
disease-specific and metastasis-free survival declined
significantly in patients with high COX-2 expression in
breast tumors (P = 0.0043 and P < 0.0001, respectively)
(Figure 5B and Table 2). Similarly, the disease-specific
and metastasis-free survival declined significantly in
patients with high IDO expression in CAFs (P = 0.0045
and P < 0.0001) (Figure 5C and Table 2). More important,
high COX-2 in tumors and high IDO1 expression in CAFs
predicted worse disease-free and metastasis-free survivals
in breast cancer patients (P < 0.0001, Figure 5D).
COX-2 and IDO inhibitors suppressed growth of
COX-2-overexpressing breast tumors in vivo
The effect of COX-2 and IDO inhibitors was evaluated
in an orthotopic model. Inoculation of MCF-7/RMF-EG-
or COX-2-overexpressing MCF-7/RMF-EG cell mixture
induced tumors in nude mice primed with 17β-estradiol
injection (Figure 6A). Tumor growth was higher in the
COX-2-overexpressing MCF-7/RMF-EG group, and a
2.4-fold of increase of tumor volume was detected at
10 weeks (P < 0.01). The COX-2-overexpressing MCF-7/
RMF-EG group was randomly divided into four subgroups
(n = 3). Intratumoral injection of vehicle (DMSO, control),
10 mg/kg of NS398, 10 mg/kg of 1-methyl-L-tryptophan,
or both inhibitors was conducted, and treatment was
continuous for another 2 weeks. As shown in Figure 6B,
tumor volume of the groups treated with NS398 or
1-methyl-L-tryptophan was smaller than that of thecontrol group. Co-treatment of COX-2 and IDO inhibitor
induced a more obvious reduction in tumor size, although
it did not show an additive effect.
Discussion
Previous studies demonstrated that IDO overexpression
increases the secretion of kynurenine to inhibit effect T
cells to promote immune escape and tumor progression
in various human cancers [27-29]. The expression of IDO
in cancer stroma has not been clarified. In addition, the
clinical significance of stromal IDO is unclear.
In this study, we provide evidence that COX-2-
overexpressing breasts cancer cells may secrete PGE2 to in-
duce IDO expression and kynurenine production in stro-
mal fibroblasts. In addition, we show that kynurenine in
the coculture-conditioned medium is produced mainly
by CAFs because IDO is not induced by COX-2 over-
expression in MCF-7 cells. An important upstream
regulator of IDO is interferon-γ. Yoshida et al. [30]
first reported that the pulmonary IDO was induced in
the mouse after intraperitoneal administration of bacterial
endotoxin or during in vivo virus infection, and this in-
duction was triggered by interferon-γ [30]. Because
interferon-γ exhibits antitumor activity on various
cancers in vitro and in vivo, it is unlikely that COX-2-
overexpressing cancer cells produce interferon-γ to
stimulate stromal IDO. For the first time, we show that
cancer cell-produced PGE2 transcriptionally upregu-
lates IDO expression through the EP4/STAT3 signaling
pathway. In vivo binding of STAT3 to IDO gene pro-
moter is confirmed by ChIP assay. Additionally, knock-
down of STAT3 totally abolishes EP4 agonist-induced
IDO expression. These data suggest that IDO is a dir-
ect transcriptional target of STAT3.
An unresolved question is why PGE2 stimulates IDO
expression in stromal fibroblasts but not in breast cancer
cells, because both cell types express EP4 receptor [31
and data not shown]. We are aware that the binding of
STAT1 to IDO promoter is reduced by PGE2 (Additional
file 3: Figure S2); therefore, it is possible that the expres-
sion level of STAT1 and STAT3 and the competition be-
tween these two STATs may determine the response of
cells to PGE2 stimulation.
The concept of oncometabolite was established by
the studies that mutations of isocitrate dehydrogenase
1 (IDH1) and IDH2 generate a novel metabolite 2-
hydroxyglutarate (2-HG) that exhibits oncogenic ac-
tivity in acute myeloid leukemia and glioma [32,33].
Subsequently, 2-HG was shown to be a competitive inhibi-
tor of α-ketoglutarate-dependent dioxygenases and inhibits
histone demethylases like Tet methylcytosine dioxygenase
2 (TET2) to change promoter methylation and gene tran-
scription [34,35]. Kynurenine represents another oncome-
tabolite, which acts as an immunosuppressor to create
Figure 5 Coexpression of cancer COX-2 and stromal IDO predicted worse patient survival. (A) Immunohistochemical staining showed
COX-2 expression in breast tumor tissues and IDO expression in tumor stroma. (B) High COX-2 expression in tumor tissues was associated with
reduced disease-specific and metastasis-free survival. (C) High IDO expression in tumor stroma also was associated with reduced disease-specific
and metastasis-free survival. (D) Coexpression of tumor COX-2 and stroma IDO predicted worse patient survival.
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Table 1 Correlation between Cox-2 and Ido-1 expression and various clinicopathologic factors
Parameters Category No. of
cases
Cox-2 expression (tumor) P value Ido-1 expression (CAF) P value
Low exp. High exp. Low exp. High exp.
Age (years) <60 years 141 73 68 0.444 69 72 0.647
≧60 years 61 28 33 32 29
Primary tumor (T) T1 82 45 37 0.002 44 38 <0.001
T2 96 52 44 54 42
T3-4 24 4 20 3 21
Nodal status (N) N0 117 77 40 <0.001 76 41 <0.001
N1-N2 85 24 61 25 60
Stage I 63 37 26 0.006 37 26 0.002
II 115 59 56 60 55
III 24 5 19 4 20
Histologic grade Grade I 18 13 5 0.122 15 3 0.003
Grade II 141 69 72 71 70
Grade III 43 19 24 15 28
CAF Ido-1 expression Low Exp. (<medium) 101 65 35 <0.001
High Exp. (≧medium) 101 35 65
Bold figures, Statistically significant.
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and metastasis [36]. A recent study demonstrated that
the tryptophan catabolism enzyme TDO is overex-
pressed in human brain tumors, and elevated secretion
of kynurenine promotes cell migration via an AhR-
dependent pathway [25].Table 2 Univariate log-rank analysis for disease-specific survi
Parameters Category No. of case
Age (years) <60 years 141
≧60 years 61
Primary tumor (T) T1 82
T2 96
T3-4 24





Histologic grade Grade I 18
Grade II 141
Grade III 43
Cox-2 expression Low Exp (<medium) 101
(Tumor) High Exp (≧medium) 101
Ido-1 expression Low Exp (<medium) 101
(CAF) High Exp (≧medium) 101
Bold figures, Statistically significant.However, the underlying mechanism by which kynure-
nine increases cell motility is still unclear. After screen-
ing of the EMT markers, we found that E-cadherin is
decreased in kynurenine-treated breast cancer cells, and
AhR is involved in this process. AhR has been shown
to integrate as a component of a novel Cul4B ubiquitinval and metastasis-free survival
DSS MeFS
No. of events P value No. of events P value
13 0.9804 41 0.7650
4 16
5 0.0283 9 <0.0001
10 34
2 14
7 0.0079 19 <0.0001
10 38
3 0.0001 5 <0.0001
10 38
4 14
0 0.2066 1 0.0269
15 41
2 15
4 0.0043 15 <0.0001
13 42
4 0.0045 9 <0.0001
13 48
Figure 6 Inhibition of tumor growth by COX-2 and IDO inhibitors in vivo. (A) MCF-7 or MCF-7-COX2 (8 × 106) cells mixed with RMF-EG (6 × 106)
cells were inoculated into the fourth mammary fat pads of 6-week-old female nude mice. Before inoculation of the cancer cell/fibroblast mixture, all
mice were primed with 6 mg/kg of 17β-estradiol twice a week for 3 weeks. Measurement of tumor growth was begun at 4 weeks after injection, and
tumor volume was continuously monitored. The difference between the groups was evaluated by repeated measures two-way ANOVA analysis. n.s.,
no significance. *P < 0.01. (B) After 10 weeks, mice injected with MCF-COX-2 and RMF-EG cells were randomly divided into four groups that received
vehicle (DMSO), NS-398 (10 mg/kg), L-1-methy-tryptophan (10 mg/kg), or both inhibitors 5 times per week. Two weeks later, animals were killed, and
tumors were isolated from mice.
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of sex steroid receptors [26]. We demonstrated that
kynurenine increases the interaction between AhR and
E-cadherin, and the AhR/E-cadherin complex also contains
Skp2, an F-box protein of SCF E3 ligase. The formation
of the E-cadherin/AhR/Skp2 complex and ubiquitination
of E-cadherin induced by kynurenine is also detectable in
A549 cells, indicating a general mechanism of kynurenine-
induced proteolysis of E-cadherin in different cancer cells.
Our results provide a novel oncometabolite function of
kynurenine to enhance cancer cell migration by degrading
E-cadherin.
The clinical validation of tumor COX-2 and stromal
IDO in this study is important to verify the cancer-
stroma interplay in cancer progression. Many histopath-
ologic studies investigated the expression of two specific
genes in the epithelial components of tumor tissues to
show their association and to demonstrate the vertical
regulation of these two genes. The correlation and clin-
ical significance of genes separately expressed in tumor
and stroma have received little attention.
However, the gene signatures in CAFs may provide
more information than originally thought. West et al.
[37] first classified two stromal gene signature from tu-
mors with solitary fibrous tumor (SFT) and desmoids-type
fibromatosis (DTF) features and showed that patients with
the expression of DTF had a favorable clinical outcome.
Their subsequent study by using public databases and
immunohistochemical approaches suggested that DTF
fibroblast signature is a common tumor stroma signature
in different types of cancers [38]. Mercier et al. [39] identi-
fied a hyperproliferative gene signature in CAFs and foundthat breast cancer patients with this signature had a poor
prognosis with tamoxifen monotherapy and a great reduc-
tion in recurrence-free survival [39]. By using a mouse
model of squamous skin carcinogenesis, Erez [40] dem-
onstrated that carcinoma cells could educate CAFs to
express proinflammatory genes to promote macrophage
recruitment, neovascularization, and tumor growth.
Additionally, this gene signature was also evident in mam-
mary and pancreatic tumors in mice and in human cancers.
By using metabolomics, molecular, and pathological
approaches, we revealed that induction of stromal IDO
by COX-2-overexpressing breast cancer cells promotes
tumor progression and predicts poor patient survival.
Results of our animal study also clearly demonstrate
the anticancer effect of COX-2 and IDO inhibitor on
COX-2-overexpressing breast cancer in vivo. A combin-
ation of IDO and COX-2 inhibitor exhibits a more obvi-
ous effect on the inhibition of tumor growth. However,
we did not find an additive effect. This can be because
(a) the number of animals in each group is small, and
(b) inhibition of COX-2 in cancer cells will attenuate
stromal IDO expression, which reduces the anticancer
activity of IDO inhibitor. Additional experiments are
needed to clarify this issue.
Conclusion
By using a metabolomics approach, we identified potential
oncometabolites involved in the crosstalk between COX-2-
overexpressing breast cancer cells and fibroblasts. Molecu-
lar study elucidates the underlying mechanism by which
this cancer/stroma interplay via COX-2 and IDO promotes
tumor progression. In addition, pathological investigation
Chen et al. Breast Cancer Research 2014, 16:410 Page 13 of 14
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IDO in the prediction of the patient’s survival. Simultan-
eous targeting of COX-2 and IDO may be a new strategy
for breast cancer treatment.
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Additional file 1: Supplementary materials and methods.
Additional file 2: Figure S1. PGE2 stimulated IDO promoter activity.
Different IDO promoter constructs were transfected into MCF-7 cells and
stimulated by PGE2. Promoter assay indicated that PGE2 activated IDO via
the −1140/-844 promoter region.
Additional file 3: Figure S2. In vivo binding of STAT3 on IDO gene
promoter in EMF-EG fibroblasts and its regulation by co-culture of
COX-2-overexpressing MCF7 cells. ChIP assay demonstrated that the
binding of STAT3 to IDO promoter was increased, whereas the binding of
STAT1 was reduced in EMF-EG fibroblasts after co-culture with
COX-2-overexpressing MCF-7 cells.
Additional file 4: Figure S3. Kynurenine induced the formation of
E-cadherin/AhR/Skp2 complex in A549 lung cancer cells. A549 cells were
treated without (−) or with (+) kynurenine, and the interaction between
E-cadherin and AhR or Skp2 was studied by immunoprecipitation and
Western blotting.
Additional file 5: Figure S4. IDO expression in cancer-associated
fibroblasts (CAFs) was increased in COX-2-overexpressing breast cancer.
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